Pronulife® IP0301 is a product with clinically proven benefits for intestinal health and immunity in infants and young children, along with combined effects with drugs on rotaviral enteritis. It also has clinically proven benefits for gut microbiota and bowel movement. End uses encompass infant formula, functional foods, and dietary supplements.

Ingredient Name: Probiotic Blend

Functions: Probiotic

Certifications & Compliance: FDA Compliant, FSSC 22000, GMP, Hazard Analysis Critical Control Point (HACCP), ISO 22000, NSF Approved

Benefit Claims (Health): Promotes Healthy Gut Microflora, Promotes Intestinal Health, Stimulates Immune System

Ask Pharm-Rx Chemical Corp. Questions

Mark Bostel avatar

Enhanced TDS

Identification & Functionality

Ingredient Name
Food Ingredients Functions
Pharma & Nutraceuticals Functions

Features & Benefits

Product Highlights
  • Clinically proven benefits to intestinal health and immunity in infants and young children and combined effect with drugs on rotaviral enteritis
  • Clinically proven benefits to gut microbiota and bowel movement
  • Specific probiotic strains naturally originate from humans and conventional food
  • Strain patents in China, Taiwan and USA
  • Strain deposit: BLI-02 at BCRC (910812); MP108 at BCRC (910483)
Product Features
  • Better efficacy
  • Stronger immunity
  • Shorter recovery time
  • Function: Glucose Control

Applications & Uses

Dosage Information

Daily dosage: 9 x 10° CFU for infants under 2 years and 1.8 x 101 CFU for children over 2 years and adults

Product Applications
  • Functional foods and dietary supplements in forms of capsules, tablets, powdered sachets, and others
  • IP0301: help support gut health, relieve rotaviral enteritis and promotes intestinal function recovery after colorectal surgery

Properties

Specifications
ValueUnitsTest Method / Conditions
Specification10¹¹cfu/g
Contents
  • Bifidobacterium animalis subsp. lactis BB-115
  • Bifidobacterium longum subsp. infantis BLI-02
  • Lactobacillus rhamnosus MP108

Regulatory & Compliance

Technical Details & Test Data

Clinical Study

Clinical Study on 120 infants and young children (9-56 months old) with rotaviral enteritis for 3 days, with 60 subjects in control group (conventional drugs) and 60 subjects in probiotic group (conventional drugs + IP0301) (* p < 0.05 vs. control, # p < 0.05 vs. the same group before intervention)

  • IP0301 has beneficial effect on rotaviral enteritis treatment

Pronulife® IP0301 - Storage and Shelf Life Conditions - 1

  • IP0301 helps relieve symptoms of rotaviral enteritis

Pronulife® IP0301 - Storage and Shelf Life Conditions - 1

  • IP0301 helps enhance immunity more

Pronulife® IP0301 - Storage and Shelf Life Conditions - 1
Clinical Study on 90 subjects undergoing colorectal resection, with 45 subjects in control group (surgery only) and 45 subjects in probiotic group (IP0301 from 8 days to 1 day prior to surgery) (* p ≤ 0.05 vs. control, # p≤ 0.05 vs. the same group before surgery)

  • IP0301 helps recover from colorectal surgery

Pronulife® IP0301 - Storage and Shelf Life Conditions - 1

  • IP0301 helps improve gut microbiota after colorectal surgery

Pronulife® IP0301 - Storage and Shelf Life Conditions - 1

  • IP0301 helps enhance immunity after colorectal surgery

Pronulife® IP0301 - Storage and Shelf Life Conditions - 1

Storage & Handling

Shelf Life
2 years
Storage and Shelf Life Conditions
  • Shelf life: 2 years
  • Storage: -16 to -20°C